"Annexin A6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Protein of the annexin family with a probable role in exocytotic and endocytotic membrane events.
Descriptor ID |
D017317
|
MeSH Number(s) |
D12.776.157.125.050.110
|
Concept/Terms |
Annexin A6- Annexin A6
- Calcimedin 67-kDa
- Calcimedin 67 kDa
- Lipocortin VI
- Calelectrin 67-kDa
- Calelectrin 67 kDa
- Calphobindin II
- Annexin VI
- Calcium and Phospholipid-Binding Protein p68
- Calcium and Phospholipid Binding Protein p68
|
Below are MeSH descriptors whose meaning is more general than "Annexin A6".
Below are MeSH descriptors whose meaning is more specific than "Annexin A6".
This graph shows the total number of publications written about "Annexin A6" by people in this website by year, and whether "Annexin A6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 0 | 1 |
2010 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2020 | 2 | 0 | 2 |
2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Annexin A6" by people in Profiles.
-
Williams SD, Smith TM, Stewart LV, Sakwe AM. Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists. Cells. 2022 09 27; 11(19).
-
Korolkova OY, Widatalla SE, Williams SD, Whalen DS, Beasley HK, Ochieng J, Grewal T, Sakwe AM. Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies. Cells. 2020 08 07; 9(8).
-
Korolkova OY, Widatalla SE, Whalen DS, Nangami GN, Abimbola A, Williams SD, Beasley HK, Reisenbichler E, Washington MK, Ochieng J, Mayer IA, Lehmann BD, Sakwe AM. Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. PLoS One. 2020; 15(4):e0231711.
-
Widatalla SE, Korolkova OY, Whalen DS, Goodwin JS, Williams KP, Ochieng J, Sakwe AM. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors. Carcinogenesis. 2019 08 22; 40(8):998-1009.
-
Koumangoye RB, Nangami GN, Thompson PD, Agboto VK, Ochieng J, Sakwe AM. Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors. Mol Cancer. 2013 Dec 19; 12(1):167.
-
Sakwe AM, Koumangoye R, Guillory B, Ochieng J. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions. Exp Cell Res. 2011 Apr 01; 317(6):823-37.
-
Francia G, Mitchell SD, Moss SE, Hanby AM, Marshall JF, Hart IR. Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. Cancer Res. 1996 Sep 01; 56(17):3855-8.